-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, as artificial intelligence has become more mature and new targets and mechanisms have become fewer and fewer, pharmaceutical companies need to invest more manpower and power to create Fist-In-Class products.
In order to improve R&D efficiency, use Existing technological means empower drug research and development, and the exploration and application of AI in the field of drugs is accelerating
.
The drug discovery process has been through to the entire life cycle
.
According to IDC data forecasts, the total value of the artificial intelligence technology application market will reach 127 billion US dollars by 2025, of which the medical industry will account for one-fifth of the market size
.
In this context, the combination of domestic medical treatment and digital technology has also developed rapidly
.
Among them, it is worth noting that in the context of increasingly showing great potential, many multinational companies have also begun to adjust the next step of research and development in China, choosing to cooperate with artificial intelligence and other companies in China, through smart cloud, Artificial intelligence technology, etc.
lay out projects such as patient education and management
.
For example, on October 11, during the Shanghai Biomedical Industry Week, AstraZeneca announced that the global R&D China Center was officially completed after the upgrade, and the Shanghai International Life Science Innovation Park and the Medical Artificial Intelligence Innovation Center were officially opened simultaneously
.
It is reported that, as an important member of the global R&D network, AstraZeneca Global R&D China Center will deeply participate in AstraZeneca’s global new drug R&D, from R&D pipeline layout, R&D strategy formulation, to full life cycle product development and launch, covering tumors and respiratory diseases.
, immune, cardiovascular, renal, metabolic, and other rare diseases widespread disease areas
.
At the same time, in the medical field, the relationship between AI technology and drug research and development is also further integrated, which is expected to help accelerate the efficiency of biomedicine research and development
.
It is understood that in the direction of "AI empowered new drug research and development", AstraZeneca has always been more prominent, and it has performed well in terms of the number of published papers, internal research and development, and external cooperation
.
At the same time, its domestic layout is also earlier.
It is reported that AstraZeneca established the China Health Internet of Things Innovation Center in Wuxi as early as 2017, which is the first open strategic collaboration platform established by a pharmaceutical company..
In addition, since 2014, Eli Lilly China has also continuously experienced the gradual upgrade of Digital Innovation 3.
0, from the establishment of digital channels and the continuous upgrading of applications in traditional models to the current full integration and deep integration of artificial intelligence, big data, and cloud technologies.
.
On November 7, 2020, Eli Lilly China also launched a psoriasis artificial intelligence simulation and management project with Shanghai Yingpu Medical Technology Co.
, Ltd.
(Airdoc)
.
In fact, in recent years, with the continuous advancement of new rounds of medical reforms such as the development of Internet medical services, mass procurement, and medical insurance reforms, multinational pharmaceutical companies are adjusting their strategies in China, and actively starting to deploy digital medical services has long been the choice of a large number of multinational pharmaceutical companies
.
According to statistics, as of last year, more than half of the world's top 50 multinational pharmaceutical companies have signed cooperation agreements with Ali Health
.
From the above point of view, multinational companies are currently very optimistic about the development of the domestic AI+ pharmaceutical industry
.
The industry predicts that as capital scrambles to enter the game, it will undoubtedly accelerate the development of the AI+ medical track.
At the same time, it will also accelerate the speed of drug R&D and innovation in the domestic pharmaceutical industry, further promote the appearance of innovation results, and benefit more patients
.
However, it is worth noting that the AI+ new drug R&D industry has the characteristics of high barriers, large technology span, and long industrial cycle, which requires a lot of capital for R&D investment
.
Therefore, both multinational pharmaceutical companies and domestic pharmaceutical companies must be prepared for a protracted battle in AI+ new drug research and development
.
In order to improve R&D efficiency, use Existing technological means empower drug research and development, and the exploration and application of AI in the field of drugs is accelerating
.
The drug discovery process has been through to the entire life cycle
.
According to IDC data forecasts, the total value of the artificial intelligence technology application market will reach 127 billion US dollars by 2025, of which the medical industry will account for one-fifth of the market size
.
In this context, the combination of domestic medical treatment and digital technology has also developed rapidly
.
Among them, it is worth noting that in the context of increasingly showing great potential, many multinational companies have also begun to adjust the next step of research and development in China, choosing to cooperate with artificial intelligence and other companies in China, through smart cloud, Artificial intelligence technology, etc.
lay out projects such as patient education and management
.
For example, on October 11, during the Shanghai Biomedical Industry Week, AstraZeneca announced that the global R&D China Center was officially completed after the upgrade, and the Shanghai International Life Science Innovation Park and the Medical Artificial Intelligence Innovation Center were officially opened simultaneously
.
It is reported that, as an important member of the global R&D network, AstraZeneca Global R&D China Center will deeply participate in AstraZeneca’s global new drug R&D, from R&D pipeline layout, R&D strategy formulation, to full life cycle product development and launch, covering tumors and respiratory diseases.
, immune, cardiovascular, renal, metabolic, and other rare diseases widespread disease areas
.
At the same time, in the medical field, the relationship between AI technology and drug research and development is also further integrated, which is expected to help accelerate the efficiency of biomedicine research and development
.
It is understood that in the direction of "AI empowered new drug research and development", AstraZeneca has always been more prominent, and it has performed well in terms of the number of published papers, internal research and development, and external cooperation
.
At the same time, its domestic layout is also earlier.
It is reported that AstraZeneca established the China Health Internet of Things Innovation Center in Wuxi as early as 2017, which is the first open strategic collaboration platform established by a pharmaceutical company..
In addition, since 2014, Eli Lilly China has also continuously experienced the gradual upgrade of Digital Innovation 3.
0, from the establishment of digital channels and the continuous upgrading of applications in traditional models to the current full integration and deep integration of artificial intelligence, big data, and cloud technologies.
.
On November 7, 2020, Eli Lilly China also launched a psoriasis artificial intelligence simulation and management project with Shanghai Yingpu Medical Technology Co.
, Ltd.
(Airdoc)
.
In fact, in recent years, with the continuous advancement of new rounds of medical reforms such as the development of Internet medical services, mass procurement, and medical insurance reforms, multinational pharmaceutical companies are adjusting their strategies in China, and actively starting to deploy digital medical services has long been the choice of a large number of multinational pharmaceutical companies
.
According to statistics, as of last year, more than half of the world's top 50 multinational pharmaceutical companies have signed cooperation agreements with Ali Health
.
From the above point of view, multinational companies are currently very optimistic about the development of the domestic AI+ pharmaceutical industry
.
The industry predicts that as capital scrambles to enter the game, it will undoubtedly accelerate the development of the AI+ medical track.
At the same time, it will also accelerate the speed of drug R&D and innovation in the domestic pharmaceutical industry, further promote the appearance of innovation results, and benefit more patients
.
However, it is worth noting that the AI+ new drug R&D industry has the characteristics of high barriers, large technology span, and long industrial cycle, which requires a lot of capital for R&D investment
.
Therefore, both multinational pharmaceutical companies and domestic pharmaceutical companies must be prepared for a protracted battle in AI+ new drug research and development
.
